Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.43 |
| ▸ | F10 | P00742 | 8/20 | 0.42 |
| ▸ | CALML3 | P27482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040632 | 0.91 | MAOB (0.42) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040748 | 0.91 | MAOB (0.47) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040342 | 0.90 | MAOB (0.48) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL7800437 | 0.88 | MAOB (0.46) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040241 | 0.87 | MAOA (0.47) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040455 | 0.87 | MAOA (0.48) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040434 | 0.86 | MAOA (0.48) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040296 | 0.86 | MAOB (0.49) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL7804227 | 0.85 | MAOB (0.46) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL6040291 | 0.85 | MAOB (0.46) | MAOBMAOAF10CALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010046987-A1 | Oxazolidinones having a sulfoximine functionality | PHARMACIA & UPJOHN COMPANY | 2001-11-29 | — | — | US | claimed |
| US-7049443-B2 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-20010046987-A1 | Oxazolidinones having a sulfoximine functionality | PHARMACIA & UPJOHN COMPANY | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046987-A1 | Oxazolidinones having a sulfoximine functionality | OXA1L, SULT1A1, SULT1E1 | MAOB 726/4885MAOA 923/4885F10 2274/4885 |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | MAOB 732/4885MAOA 1179/4885F10 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.